Hematopoietic cytokines as tumor markers in breast malignancies. A multivariate analysis with ROC curve in breast cancer patients

被引:19
|
作者
Lawicki, S. [1 ]
Bedkowska, G. E. [1 ]
Wojtukiewicz, M. [2 ]
Szmitkowski, M. [1 ]
机构
[1] Med Univ Bialystok, Dept Biochem Diagnost, PL-15269 Bialystok, Poland
[2] Med Univ Bialystok, Dept Oncol, PL-15269 Bialystok, Poland
来源
ADVANCES IN MEDICAL SCIENCES | 2013年 / 58卷 / 02期
关键词
breast cancer; CA; 15-3; HGFs; tumor markers; COLONY-STIMULATING FACTOR; FACTOR M-CSF; STEM-CELL FACTOR; SERUM-LEVELS; CIRCULATING LEVELS; COLORECTAL-CANCER; OVARIAN-CANCER; FACTOR-I; ENDOMETRIAL; CARCINOMAS;
D O I
10.2478/ams-2013-0023
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Purpose: Plasma levels of selected hematopoietic cytokines: interleukin 3 (IL-3), stem cell factor (SCF), granulocyte-macrophage colony-stimulating factor (GM-CSF), granulocyte colony-stimulating factor (G-CSF) and macrophage colony-stimulating factor (M-CSF), and the tumor marker carcinoma antigen 15-3 (CA 15-3) in breast cancer (BC) patients were investigated and compared to control groups: benign breast tumor patients and healthy subjects. Material/Methods: Cytokine levels were determined by ELISA, CA 15-3-using the CMIA method. Results: A significant differences in the concentration of cytokines (with the exception of IL-3) and CA15-3 between the groups of BC patients, benign breast tumor patients and the healthy controls have been demonstrated. M-CSF has demonstrated higher or equal to CA 15-3 values of diagnostic sensitivity, specificity and the predictive values of positive and negative test results. The M-CSF area under the ROC curve (AUC) was the largest from all the cytokines tested and marginally lower than the AUC of CA 15-3. Conclusion: These findings suggest the usefulness of M-CSF in diagnosing breast cancer, especially when discriminating between cancer and non-carcinoma lesions.
引用
收藏
页码:207 / 215
页数:9
相关论文
共 50 条
  • [21] Cytokeratin and mammaglobin as tumor markers in patients with high risk breast cancer
    PF Ferrucci
    C Rabascio
    C Corsini
    F Tealdo
    M Paolucci
    F Bertolini
    H El Taani
    G Martinelli
    Breast Cancer Research, 2 (Suppl 1)
  • [22] Relationship between bone scintigraphy and tumor markers in patients with breast cancer
    Mustafa Yildiz
    Baha Oral
    Mehmet Bozkurt
    Azem Cobaner
    Annals of Nuclear Medicine, 2004, 18 : 501 - 505
  • [23] Development of Tumor Markers for Breast Cancer Immunotherapy
    Fang, Qianqian
    Shen, Guoshuang
    Xie, Qiqi
    Guan, Yumei
    Liu, Xinlan
    Ren, Dengfeng
    Zhao, Fuxing
    Liu, Zhilin
    Ma, Fei
    Zhao, Jiuda
    CURRENT MOLECULAR MEDICINE, 2024, 24 (05) : 547 - 564
  • [24] A population-based analysis of secondary malignancies in breast cancer patients receiving breast reconstruction
    Rene Warschkow
    Thomas Cerny
    Bruno M Schmied
    Ulrich Güller
    Beat Thuerlimann
    Markus Joerger
    British Journal of Cancer, 2016, 115 : 80 - 84
  • [25] A population-based analysis of secondary malignancies in breast cancer patients receiving breast reconstruction
    Warschkow, Rene
    Cerny, Thomas
    Schmied, Bruno M.
    Guller, Ulrich
    Thuerlimann, Beat
    Joerger, Markus
    BRITISH JOURNAL OF CANCER, 2016, 115 (01) : 80 - 84
  • [26] The Role of Tumor Markers: Carcinoembryonic Antigen and Cancer Antigen 15-3 in Patients With Breast Cancer
    Khushk, Maimoona
    Khan, Adil
    Rehman, Abdur
    Sheraz, Sehrish
    Tunio, Yar Muhammad
    Rehman, Kubra
    Rehman, Duaa
    Ahmed, Moiz
    Abbas, Kiran
    Khan, E. Muhammad
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2021, 13 (07)
  • [27] Standards, Options and Recommendations (SOR) for tumor markers in breast cancer
    Basuyau, JP
    Blanc-Vincent, MP
    Bidart, JM
    Daver, A
    Deneux, L
    Eche, N
    Gory-Delabaere, G
    Pichon, MF
    Riedinger, JM
    BULLETIN DU CANCER, 2000, 87 (10) : 723 - 737
  • [28] Other malignancies in patients with breast cancer: a single institute experience
    Erkan Dogan
    Sercan Aksoy
    Omer Dizdar
    Didem S. Dede
    Cagatay Arslan
    Yavuz Ozisik
    Kadri Altundag
    Medical Oncology, 2010, 27 : 1434 - 1435
  • [29] Other malignancies in patients with breast cancer: a single institute experience
    Dogan, Erkan
    Aksoy, Sercan
    Dizdar, Omer
    Dede, Didem S.
    Arslan, Cagatay
    Ozisik, Yavuz
    Altundag, Kadri
    MEDICAL ONCOLOGY, 2010, 27 (04) : 1434 - 1435
  • [30] Biological ageing and frailty markers in breast cancer patients
    Brouwers, Barbara
    Dalmasso, Bruna
    Hatse, Sigrid
    Laenen, Annouschka
    Kenis, Cindy
    Swerts, Evalien
    Neven, Patrick
    Smeets, Ann
    Schoeffski, Patrick
    Wildiers, Hans
    AGING-US, 2015, 7 (05): : 319 - 333